The Intricacies of Polypharmacy and Drug Interactions in Schizophrenia Treatment

Introduction: Polypharmacy is frequently practiced in the management of schizophrenia due to its chronic nature, recurrent relapses, and associated comorbidities. While combining psychotropic medications may benefit patients with treatment-resistant symptoms, it poses risks such as drug–drug interactions (DDIs), adverse effects, and reduced medication adherence. The absence of uniform pre-scribing standards further complicates clinical decision-making. Methods: This narrative review was conducted using a scoping methodology. Databases including Pub-Med, Scopus, and Web of Science were searched for English-language publications from 2000 to 2024. Search terms included “schizophrenia,” “polypharmacy,” “drug–drug interactions,” “clinical out-comes,” and “pharmacogenetics.” Eligible sources included clinical trials, observational studies, sys-tematic reviews, and treatment guidelines. Exclusion criteria were non-English articles, gray literature, and individual case reports. Results: Polypharmacy is reported in 30–60% of individuals with schizophrenia, especially in institu-tionalized or treatment-resistant populations. Treatment regimens often involve multiple antipsychotics along with adjunctive antidepressants or mood stabilizers. This approach is associated with increased risks of metabolic syndrome, cardiovascular events (e.g., QT prolongation), extrapyramidal symptoms, and decreased adherence. Interindividual variability in pharmacogenetics further affects drug efficacy and safety. Innovative approaches like genotype-guided therapy and computerized clinical decision-support systems are promising but not yet widely implemented. Discussion: Although polypharmacy may offer symptomatic relief in specific scenarios, it requires careful management due to its potential to cause harm. Rational prescribing, close monitoring, and attention to individual patient factors such as pharmacogenetic profiles are essential to optimize ther-apy. Conclusion: Ensuring a balance between therapeutic benefit and adverse effects is crucial when em-ploying polypharmacy in schizophrenia treatment. Integrating personalized medicine strategies, regular monitoring, and deprescribing practices when feasible can enhance clinical outcomes and patient safety.